Summary
The effects of immunisation programmes that have existed for several decades in developed countries are demonstrated by the decrease and even eradication of smallpox, poliomyelitis, measles, mumps and hepatitis B.
Cost, health policy and spontaneous evolution in the incidence of communicable diseases have a decisive influence on the use of a vaccine. Investment in vaccination policy has to be encouraged to maintain this progress made in the control of infectious diseases and to meet new challenges.
Studies re-evaluating ongoing immunisation programmes are scarce. Nevertheless, it can be concluded that for vaccination against hepatitis B in professionally exposed at-risk populations, arguments for positive returns are consistent. The same holds for vaccination against S. pneumoniae and for influenza virus in the elderly. The results of the economic evaluation of revaccination against measles, when insufficient coverage exists, are inconclusive. Universal vaccination of children against Haemophilus influenzae type b (Hib) and of children of hepatitis B-positive mothers against hepatitis may require costs to be paid in order to gain extra health benefits.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Alter M, Hadler SC, Margolis HS, Alexander WJ, Pin YA HU, et al. The changing epidemiology of hepatitis B in the US. Need for alternative vaccination strategies. Journal of the American Medical Association 263: 1218–1222, 1990 Annual 1992
American Medical Association Drug Evaluations Annual. Immunization practices in drug evaluations. Chicago, 1991
Arday DR, Kanjarpane DD, Kelley PW. Mumps in the US Army 1980–86: should recruits be immunized? American Journal of Public Health 79: 471–474, 1989
Arevalo JA, Washington AE. Cost-effectiveness of prenatal screening and immunization for hepatitis b virus. Journal of the American Medical Association 259: 365–369, 1988
Axnick WW, Shavell SM, Witte JJ. Benefits due to immunization against measles. Public Health Reports 84: 673–680, 1969
Beale AJ. Poliovaccines: time for a change in immunisation policy. Lancet 335: 839–842, 1990
Bégué P. Le calendrier des vaccinations, le présent et le futur. Revue du Praticien 40: 2613–2616, 1990
Berger SA, Ginsberg GM, Slater PM. Cost-benefit analysis of routine mumps and rubella vaccination of Israeli infants. Israeli Journal of Medical Science 26: 74–80, 1990
Bijlmer HA. Worldwide epidemiology of H. influenzae, industrialised versus non-industrialised countries. Vaccine (Suppl.): 5–9, 1991
Bloom BR, Murray CJL. Tuberculosis: commentary on a reemergent killer. Science 257: 1055–1064, 1992
Bogaert M, Reuse J. Gecommentarieerd geneesmiddelenrepertorium 1991. Belgisch Centrum Farmacotherapeutische Informatie, Ministerie van Volksgezondheid en Leefmilieu, Brussels 1991
Bytchenko B. Viral hepatitis in the European region. Report of the WHO Technical Advisory Group on viral hepatitis, December, 1985
Chang MH, Tsen YJ, Hsu HY, Lee CH, Sung JL, et al. Seroepidemiology of hepatitis B virus infection in Taipei, 1989. Five years after a mass hepatitis B vaccination program. Proceedings of the 7th Asian Congress of Pediatrics, Perth, Australia, May 5–10, 1991
Cochi SL, Broome CV, Hightower AW. Immunisation of US children with haemophilus influenzae Type B polysaccharide vaccine. A cost-effectiveness model of strategy assessment. Journal of the American Medical Association 253: 521–529, 1985
Coester CH, Avonts D, Colaert J, Desmyter J, Piot P. Syphilis, hepatitis B and cytomegalovirus in homosexual men in Antwerp. British Journal of Venereal Diseases 60: 48–51, 1984
Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobal era. Science 257: 1050–1055, 1992
Communicable Disease Report, Measles Surveillance 1960–89, England and Wales, Weekly Edition 25, 1990
Conway SP. BCG vaccination in children. British Medical Journal 301: 1059–1060, 1990
Curwen M, Dunnel K, Ashley J. Hidden influenza deaths. British Medical Journal 300: 896, 1990
D’Amelio R, Matricadi PM, Biselli R, Stroffolino T, Mele A, et al. Changing epidemiology of hepatitis B in Italy: public health implications. American Journal of Epidemiology 135: 1012–1018, 1992
Davis RM, Markowitz LE, Preblud SR, Orenstein WA, Hinman AR. A cost-effectiveness analysis of measles outbreak control strategies. American Journal of Epidemiology 126: 450–459, 1987
De Groote J. Hepatitis A: epidemiologie, actieve en passieve beschutting. Tijdschrift voor Geneeskunde 48: 15–21, 1992
Dewals P, Dauffenbach S. Immunization against influenza in nursing homes in Brussels. Poster. Options for the control of influenza, Courchevel, September, 1992
Ducoffre G, Walckiers D, Glupczynski Y, Verbist L, Verhaegen J, et al. Evolution of pneumococcal infections in Belgium from 1986 to 1991. Revue d’Epidémiologie et de Sauté Publique, in press, 1993
Eddieston A. Hepatitis. Lancet 335: 1142–1145, 1990
Eskola J, Peltola H, Takala AK, Käyhty H, Hakulinen M, et al. Efficacy of Haemophilus influenzaetype b polysaccharidediphtheria toxoid conjugate vaccine in infancy. New England Journal of Medicine 317: 717–722, 1987
Eskola J, Takola A, Kahthy H, Peltola H, Mäkelä PH. Experience in Finland with Haemophilus influenzae type b vaccines. Vaccine 9: 14–16, 1991
Fattal-German M, Taillandier J, Mathieu D, Bizzini B. Pneumococcal vaccination of elderly individuals. Vaccine 9: 542–544, 1991
Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics 1: 20–31, 1992
Gable CB, Holzer SS, Engelhart L, Friedman RB, Smeltz F, et al. Pneumococcal vaccine. Efficacy and associated cost savings. Journal of the American Medical Association 264: 2910–2915, 1990
Gervais A, Sutter S. Epidemiology of invasive type b infections in Geneva, Switzerland 1976 to 1989. Pediatric Infectious Diseases Journal 10: 370–374, 1990
Ginsberg GM, Tulchinsky TH. Costs and benefits of a second measles inoculation of children in Israel, the West Bank and Gaza. Journal of Epidemiology and Community Health 44: 274–280, 1990
Goudeau A &the European Regional Study Group. Epidemiology and eradication strategy for hepatitis B in Europe. Vaccine 8: 113–116, 1990
Grabenstein JD, Hartzema AG, Guess HA, Johnston WP, Rittenhouse BE. Community pharmacists as immunization advocates. Cost-effectiveness of a cue to influenza vaccination. Medical Care 30: 503–513, 1992
Hall AJ, Greenwood BM, Whittle H. Modern vaccines. Practice in develo** countries. Lancet 335: 774–777, 1990
Hatziandreu EJ, Hatzakis A, Hatziyannis S, Kane M, Weinstein M. Cost-effectiveness of hepatitis-b vaccine in Greece. A country of intermediate HBV Endemicity. International Journal of Technology Assessment 7: 256–262, 1991
Hay JW, Daum RS. Cost-Benefit analysis of two strategies for prevention of Haemophilus influenzaetype b infection. Pediatrics 80: 319–329, 1987
Hayashi J, Nakashima K, Noguchi A, Morofuji M, Kashiwagi S. Cost-effectiveness of intradermal vs. subcutaneous hepatitis B vaccination for the mentally handicapped. Journal of Infection 23: 39–45, 1991
Helliwell BE, Drummond MF. The costs and benefits of preventing influenza in Ontario’s elderly. Canadian Journal of Public Health 79: 175–180, 1988
Hinman AR, Koplan JP, Orenstein WA, Brink EW, Nkowane EW. Live or inactivated poliomyelitis vaccine; an analysis of benefits and risks. American Journal of Public Health 78: 291–295, 1988
Hinman AR, Orenstein WA. Immunisation practice in developed countries. Lancet 335: 707–710, 1990
Horwitz O, Grünfeld K, Lysgaard-hansen B, Kjeldsen K. The epidemiology and natural history of measles in Denmark. American Journal of Epidemiology 100: 136–149, 1974
Hudson CP. How AIDS forces reappraisal of hepatitis B virus control in sub-Saharan Africa. Lancet 336: 1364–1367, 1990
Hutchison BG, Stoddart GL. Cost-effectiveness of primary tetanus vaccination among elderly Canadians. Canadian Medical Association Journal 139: 1143–1151, 1988
Infectious Diseases and Immunization Committee, Canadian Pediatric Society. Hepatitis B in Canada: the case for universal vaccination. Canadian Medical Association Journal 146: 25–29, 1992
Jacques P. Sero-epidemiologie van hepatitis B bij 20 000 werknemers uit de gezondheidssector. Thesis, Catholic University Leuven, 1983
Jacques P. Hepatitis B vaccination amoung Belgian health care workers. 1st International Congress on Occupational Health for Health Care Workers, Freiburg, 1992
Jönsson J, Horisberger B, Bruguera M, Matter L. Cost-benefit analysis of hepatitis-b vaccination. A computerized decision model for Spain. International Journal of Technology Assessment 7: 379–402, 1991
Klugman KP. Pneumococcal resistance to antibiotics. Clinical Microbiology Review 3: 171–196, 1990
Koplan JP, Preblud SR. A benefit-cost analysis of mumps vaccine. American Journal of Diseases of Children 136: 362–364, 1982
Krause RM. The origin of plagues: old and new. Science 257: 1073–1078, 1992
Lahaye D, Strauss P, Baleux C, Van Ganse W. Cost-benefit analysis of hepatitis B vaccination. Lancet 2: 441–443, 1987
Leese B, Bosanquet N. Immunisation in the UK: policy review and future economic options. Vaccine 10: 491–499, 1992
Livartowski A, Guyot G, Dabernat H, Carrere C, Reinert P. Epidemiologie des meningites à H. influenzaetype b dans deux départements français. Archives Français de Pédiatrie 46: 175–179, 1989
Martens LL, Ten Velden GHM, Bol P. De kosten van vaccinatie tegen Haemophilus influenzaetype b. Nederlands Tijdschrift voor Geneeskunde 135: 16–20, 1991
Martens LL. De kosten-effectiviteit van screening van zwangeren op hepatitis B. Tijdschrift voor Sociale Gezondheidszorg 67: 379–382, 1989
Mast EE, Berg JL, Hanrahan LP, Wassell JT, Davis JP. Risk factors for measles in a previously vaccinated population and cost-effectiveness of revaccination strategies. Journal of the American Medical Association 264: 2529–2533, 1990
Mauskopf JA, Bradley CJ, French MT. Benefit-cost analysis of hepatitis B vaccine programs for occupationally exposed workers. Journal of Occupational Medicine 33: 691–708, 1991
Modlin JF. Poliovirus. In Mandell et al. (Eds) Principles and practice of infectious diseases, Churchill Livingstone Inc., New York, 1990
Morbidity and Mortality Weekly Reports. H. influenzaeb conjugate vaccines for the prevention of H. influenzaetype b disease among infants and children two months of age and older. Immunization Practices Advisory Committee. Report No. 40, pp. 1–7, 1991
Morbidity and Mortality Weekly Reports. Measles prevention. Report No. 31, pp. 217–231, 1982
Morbidity and Mortality Weekly Reports. Update on Hepatitis B prevention. Centers for Disease Control. Report No. 36, pp. 353–360, 1987
Moxon ER, Rappuoli R. Haemophilus influenzae infections and whoo** cough. Lancet 335: 1324–1329, 1990
Mulley AG, Silverstein MD, Dienstag JL. Indication for use of hepatitis B vaccine based on cost-effectiveness analysis. New England Journal of Medicine 307: 644–652, 1982
Nederlandse Gezondheidsraad. Vaccination against Haemophilus influenzae typeb, Report 1991/14, The Hague, 1991
Nicoll A, Elliman D, Begg NT. Immunisation: causes of failure and strategies and tactics for success. British Medical Journal 299: 808–812, 1989
Onorato IM, Wassilak SG, Meade B. Efficacy of whole pertussis vaccine in preschool children in the United States. Journal of the American Medical Association 267: 2745–2749, 1992
Patriarca PA, Arden NH, Koplan JP, Goodman RA. Prevention and control of type a influenza infections in nursing homes. Benefits and costs of four approaches using vaccination an amantadine. Annals of Internal Medicine 107: 732–740, 1987
Peltola H, Kurki T, Virtanen M, Nissinen M, Karanko V, et al. Rapid effect on endemic measles, mumps and rubella of nationwide vaccination programme in Finland. Lancet 18: 137–139, 1986
Perez-Tirse J, Gross PA. Review of cost-benefit analyses of influenzae vaccine. PharmacoEconomics 2: 198–206, 1992
Piot P, Goilav C, Kegels E. Hepatitis B: transmission by sexual contact and needle sharing. Vaccine 8: 37–39, 1990
Preblud SR, Orenstein WA, Koplan JP, Bart KJ, Hinman AR. A benefit-cost analysis of childhood varicella vaccination programme. Postgraduate Medical Journal 61 (Suppl. 4): 17–22, 1985
Preblud SR. Varicella: complications and costs. Pediatrics 78 (Suppl.): 728–735, 1986
Robbins A. Progress towards vaccines we need and do not have. Lancet 335: 1436–1438, 1990
Russell LB. Is prevention better than cure? The Brookings Institution, Washington, DC, 1986
Sellick JA. The economics of screening for measles. PharmacoEconomics 2: 440–443, 1992
Shann F. Pneumococcus and influenza. Lancet 335: 898–901, 1990
Shapiro ED. Pertussis vaccines. Seeking a better mousetrap. Journal of the American Medical Association 267: 2788–2790, 1992
Sherlock S. Hepatitis B: the disease. Vaccine 8: 6–9, 1990
Shlian DM, Matchar D, Seymann GB. Cost-effectiveness evaluation of measles immunization strategies on a college campus. Family Practice Research Journal 11: 193–207, 1991
Snacken R, Yane F, Van Casteren V. Surveillance of acute respiratory infections and influenza in Belgium. Summary of the season 1991–1992. Archives of Public Health, in press, 1992
Snacken R, Lion J, Van Casteren V, Cornelis R, Yane F, et al. Five years of sentinel surveillance of acute respiratory infections (1985–1990): the benefits of an influenza early warning system. European Journal of Epidemiology 8: 485–490, 1992
Skolnick A. Should insurance cover routine immunizations? Journal of the American Medical Association 265: 2453–2454, 1991
Spanjaard L, Bol P, Ekker W, Zanen HC. De incidentie van bacteriële meningitis in Nederland; vergelijking van drie registratiesystemen. Nederlands Tijdschrift voor Geneeskunde 129: 355–359, 1985
Takala AK, Eskola J, Palmgren J, Rönnberg PR, Kela E, et al. Risk factors of invasive Haemophilus influenzaetype b disease among children in Finland. Journal of Pediatrics 115: 694–701, 1989
Thomas IL. Cost effectiveness of antenatal hepatitis B screening and vaccination of infants. Australian and New Zealand Journal of Obstetrics and Gynaecology 30: 331–335, 1990
Tormans G, Van Damme P, Carrin G, Clara R, Eylenbosch W. Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis b virus — the case of Belgium. Social Science and Medicine, in press, 1993
Tormans G, Van Damme P, Van Doorslaer E. Cost-effectiveness analysis of hepatitis A prevention in travellers. Vaccine 10 (Suppl. 1): 88–92, 1992
Van Damme P, Eylenbosch W, Clara R. Hepatitis B and the newborn’s situation in Belgium. Economisch Studie en Onderzoeks Centrum, University of Antwerp, 1990
Van der Veken J. Registratie van mazelen en bof in België door de huisartsenpeilpraktijken. Vlaams Huisartsen Instituut 10: referatendag, in press, 1992
Van Overbeke M, Vandepitte J, Blogie M, Yourassowsky E. Pneumococceninfecties en vaccinatie. Tijdschrift voor Geneeskunde 41: 555–560, 1985
Walckiers D, Stroobant A, Vandepitte J, Verbist L, Wauters G. Surveillance des maladies infectieuses en Belgique par un réseau de laboratoires vigies. Application à Campylobacter et Yersinia enterocolitica. Expérience de sept années. Médecine et Maladies Infectieuses 21: 244–249, 1991
Walckiers D, Stroobant A, Lamotte JM, Thiers G. Epidémiologie de la poliomyélite en Belgique. Archives Belges de Médecine Sociale, Hygiène, Médecine du Travail et Médecine Légale 41: 341–354, 1983
Weekly Epidemiology Records. Measles in 1990. United States of America, Vol. 37, pp. 276–279, 1991
Weekly Epidemiology Records. Measles surveillance in 1988, Canada, Vol. 37, pp. 284–286, 1990
Weekly Epidemiology Records. Measles surveillance, 1982–1990, Belgium, Vol. 43, pp. 314–317, 1991
Weekly Epidemiology Records. Measles surveillance in 1988, Canada, Vol. 37, pp. 284–286, 1990
Weekly Epidemiology Records. Measles surveillance. Interruption of natural transmission, Czechoslovakia, Vol. 58, pp. 85–86, 1983
Weisbrod BA. Costs and benefits of medical research: a case study of poliomyelitis. Journal of Political Economy 79: 527–544, 1971
White CC, Koplan JP, Orenstein WA. Benefits, risks and costs of immunization for measles, mumps and rubella. American Journal of Public Health 75: 739–744, 1985
White JM, Gillam SJ, Begg NT, Farrington CP. Vaccine coverage: recent trends and future prospects. British Medical Journal 304: 682–684, 1992
Willems JS, Sanders CR. Cost-effectiveness and cost-benefit analysis of vaccines. Journal of Infectious Diseases 144: 486–493, 1981
World Health Organization. Report of a WHO meeting: prevention of liver cancer. World Health Association Technical Reports Series 691, 1983
World Health Organization. Expanded programme on immunization. Information system. Summary for the WHO — European region. WHO Expanded Program on Immunisation, CEIS90.1 EU, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van den Oever, R., de Graeve, D., Hepp, B. et al. Pharmacoeconomics of Immunisation. Pharmacoeconomics 3, 286–308 (1993). https://doi.org/10.2165/00019053-199303040-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199303040-00005